This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Generation Bio’s 8K filing here.
Generation Bio Company Profile
Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.
Recommended Stories
- Five stocks we like better than Generation Bio
- Transportation Stocks Investing
- Globalstar: The Next Big Satellite Winner After Deal With Apple?
- What is a Death Cross in Stocks?
- Archer Aviation: Taking Off in Tokyo and Beyond?
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- 3 Fast-Growing Stocks Analysts See Doubling in Price
